Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366431 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain
A Phase 2 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
NCT00366431 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 420 participants.
The verdict
NCT00366431, a Phase 2 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
Study Summary
The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of MOA-728 in subjects with Opioid-Induced Bowel Dysfunction (OIBD) with associated chronic non-malignant pain.
Interventions
- DRUG MOA-728
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2006-08 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00366431
The ClinicalTrials.gov registry entry for NCT00366431 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MOA-728 is the first listed.
NCT00366431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00366431 about?
NCT00366431 is a clinical study titled "Study Evaluating Oral MOA-728 for the Treatment of Opioid-Induced Bowel Dysfunction (OIBD) in Subjects With Chronic Non-Malignant Pain". The primary purpose of the protocol is to evaluate the safety, efficacy, and tolerability of MOA-728 in subjects with Opioid-Induced Bowel Dysfunction (OIBD) with associated chronic non-malignant pain.
What is the current status of trial NCT00366431?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2006-08. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00366431?
The interventions under investigation include: MOA-728 (DRUG).
Who is sponsoring clinical trial NCT00366431?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.